Literature DB >> 25819815

Prostate cancer: beware of disseminated intravascular coagulation.

Mihir Desai1, Babbin John2, Gillian Evans3, Ben Eddy2.   

Abstract

Disseminated intravascular coagulation (DIC) is a pathological systemic condition resulting from aberrant activation of the coagulation system. It is characterised by the release and activation of procoagulants into the blood, with an associated consumption coagulopathy. Its association with solid and haematological malignancies is well described in literature. This case describes an elderly man, known to have prostate cancer, who following transurethral resection of the prostate developed DIC with haematuria, spontaneous ecchymoses and mucosal bleeding. Subsequent investigations revealed a prostate-specific antigen (PSA) >1000 µg/L, and staging CT showed multiple sclerotic metastatic lesions affecting the thoracic and lumbar vertebra, as well as infiltration into his left femur. Coagulation normalised with blood products and vitamin K within 1 week, and the patient responded to antiandrogen therapy with a reduction in pain and PSA on discharge. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25819815      PMCID: PMC4386315          DOI: 10.1136/bcr-2014-206814

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  34 in total

1.  Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.

Authors:  F B Taylor; C H Toh; W K Hoots; H Wada; M Levi
Journal:  Thromb Haemost       Date:  2001-11       Impact factor: 5.249

2.  Cancer and DIC.

Authors:  M Levi
Journal:  Haemostasis       Date:  2001

Review 3.  Management of the spectrum of hormone refractory prostate cancer.

Authors:  Noel W Clarke
Journal:  Eur Urol       Date:  2006-06-02       Impact factor: 20.096

Review 4.  Disseminated Intravascular Coagulation (DIC) in cancer.

Authors:  Hussain I Saba; Genevieve A Morelli; Rashid I Saba
Journal:  Cancer Treat Res       Date:  2009

Review 5.  Disseminated intravascular coagulation due to malignancy.

Authors:  R W Colman; R N Rubin
Journal:  Semin Oncol       Date:  1990-04       Impact factor: 4.929

6.  Carcinoma of the prostate presenting as acute disseminated intravascular coagulation.

Authors:  J I Spector; H Zimbler
Journal:  CMAJ       Date:  1987-03-15       Impact factor: 8.262

Review 7.  Disseminated intravascular coagulation: diagnosis and treatment.

Authors:  T Baglin
Journal:  BMJ       Date:  1996-03-16

Review 8.  Paclitaxel and docetaxel in prostate cancer.

Authors:  C Obasaju; G R Hudes
Journal:  Hematol Oncol Clin North Am       Date:  2001-06       Impact factor: 3.722

Review 9.  Abiraterone in prostate cancer: a new angle to an old problem.

Authors:  Mark N Stein; Susan Goodin; Robert S Dipaola
Journal:  Clin Cancer Res       Date:  2012-03-26       Impact factor: 12.531

10.  Experience with degarelix in the treatment of prostate cancer.

Authors:  Neal D Shore
Journal:  Ther Adv Urol       Date:  2013-02
View more
  3 in total

1.  Disseminated Intravascular Coagulation and Excessive Fibrinolysis (DIC XFL) Syndrome in Prostate Cancer: A Rare Complicated Disorder.

Authors:  Azhar Bin Amir Hamzah; Yew Maw Choo; Mohamed Azmi Hassali; Fahad Saleem; Ashutosh Kumar Verma
Journal:  J Clin Diagn Res       Date:  2017-01-01

2.  Leukoerythroblastosis in castration-resistant prostate cancer: A clue to diffuse bone marrow carcinomatosis.

Authors:  Frank Sheng Fan; Chung-Fan Yang
Journal:  Clin Pract       Date:  2019-05-06

3.  Comparative Analysis of Proteomes and Phosphoproteomes in Patients with Prostate Cancer Using Different Surgical Conditions.

Authors:  Hee-Sung Ahn; Jeonghun Yeom; Hwangkyo Jeong; Won Young Park; Ja Yoon Ku; Byeong Jin Kang; Kyung Hwan Kim; Chan Ho Lee; Sangheon Song; Sun Sik Bae; Kyunggon Kim; Hong Koo Ha
Journal:  World J Mens Health       Date:  2022-01-01       Impact factor: 6.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.